Skip to main content
Lixiana-H-C-PSUSA-00010387-201610: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Lixiana-H-C-PSUSA-00010387-201610: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

8 Aufrufe
Herunterladen
Pharmazeutisch

Lixiana-H-C-PSUSA-00010387-201610: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Fortschrittliche pharmazeutische Formulierung für gezielte therapeutische Intervention.

Dosierung

Lixiana-H-C-PSUSA-00010387-201610: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Stärke

Lixiana-H-C-PSUSA-00010387-201610: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Packungsgröße

Lixiana-H-C-PSUSA-00010387-201610: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Form

Lixiana-H-C-PSUSA-00010387-201610: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Quelle

European Medicines Agency

Quelle anzeigen

Sicherheitsprofil

Kontraindikationen

Lixiana-H-C-PSUSA-00010387-201610: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Nebenwirkungen

Lixiana-H-C-PSUSA-00010387-201610: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Verwandte klinische Artikel